Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

PR Newswire April 13, 2022

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology

PR Newswire March 24, 2022

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis

PR Newswire March 22, 2022

Halozyme Appoints Moni Miyashita to Board of Directors

PR Newswire March 15, 2022

HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS

PR Newswire February 22, 2022

HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL

PR Newswire February 9, 2022

Halozyme Appoints New Chief Financial Officer

PR Newswire February 2, 2022

HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK

PR Newswire January 10, 2022

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

PR Newswire January 4, 2022

HALOZYME APPOINTS NEW GENERAL COUNSEL

PR Newswire December 13, 2021

HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM

PR Newswire December 9, 2021

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

PR Newswire December 1, 2021

Halozyme to Present at Upcoming Investor Conferences

PR Newswire November 18, 2021

Halozyme Reports Third Quarter 2021 Results

PR Newswire November 2, 2021

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

PR Newswire October 19, 2021

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

PR Newswire September 15, 2021

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

PR Newswire August 26, 2021

Halozyme Reports Second Quarter 2021 Results

PR Newswire August 9, 2021

Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference

PR Newswire July 30, 2021

Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call

PR Newswire July 27, 2021